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On the plausibility of late neuropsychiatric manifestations associated with the COVID-19 pandemic
Dear Sir
Recognition of the association between acute and subacute different
neuropsychiatric manifestations with the infection by severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the on-
going coronavirus disease 2019 (COVID-19) pandemic, is progressively
being recognized [1]. The potential emergence of late onset neu-
ropsychiatric manifestations after infection with SARS-CoV-2 remains to be
discussed. After the “Spanish” influenza pandemic in the 20th century,
an outbreak of encephalitis lethargica (EL) [2], a neuropsychiatric
disorder of possible autoimmune origin emerged occurring soon after
the acute phase or at some time later [3]. It's worthwhile to highlight
that manifestations of EL such as sleep disturbance, fatigue, psychosis,
catatonia, movement disorders among others were identified in pre-
vious historical epidemics since the 15th century [3]. Molecular mi-
micry leading to damage of the brainstem respiratory pace-maker [4]
and occurrence of neurological autoimmune disorders after SARS-CoV-
2 infection (Gillian Barré syndrome and its variants) [5,6] are indicative
of the potential inducer of autoimmunity involving the nervous system
on the long-term.
Apart from a single study showing an association of seropositivity
for specific coronavirus (HCoV-NL63) with chronic mood disorder [7],
nothing is known about the possibility of late neuropsychiatric manifes-
tations associated with coronavirus infections.
The is indirect evidence (Fig. 1) supporting the biological patho-
physiology of late occurrence of neuropsychiatric manifestations after
SARS-CoV-2 infection.
Proinflammatory cytokines such as the interleukin-6 (IL-6) [8] or
tumour necrosis factor alpha (TNF-α)9 are associated with development
of late onset neuropsychiatric manifestations. COVID-19 is associated with
systemic inflammatory storm with a massive release of cytokines,
chemokines, including IL-6 and TNF-α10. Delirium it's not rare in pa-
tients with COVID-19 [1], suggesting that at least acutely, significant
break of blood brain barrier and neuroinflammation occurs. Latent viral
chronic brain infection caused by viruses, per example the human
herpes virus 6 infections or the measle virus are associated with late
cognitive and behaviour disturbances [9,10]. In murine models, cor-
onaviruses can invade the brain and cause chronic infection [11,12].
The presence of coronavirus was demonstrated in the brain tissue in a
single patient after SARS-CoV infection [13]. Very low levels of SARS-
CoV-2 was detected in very few patients who died from COVID-19 [14].
Despite the inexistence of documented cases of 2019-nCoV chronic
brain infection, the invasiveness and neurotropism of the virus
[15],obliges to leave this possibility open.
SARS-CoV-2 is worldwide distributed and affecting people with
different genetic background. The virus itself, is also genetically
adapting to humans [16]. Hence, in the context of an infinitude of
virus-host interactions, the possibility of late neuropsychiatric manifes-
tations after SARS-CoV-2 infection should be considered. Careful mon-
itoring of chronic or late neuropsychiatric manifestations is important to
uncover mechanisms of the disease and guide interventions to prevent. Most
patients with SARS-CoV-2 infection are asymptomatic and the durability
of serological markers of infection is unknow. This might preclude stu-
dies based on serological status. Due to the large variability of SARS-
CoV-2 infection prevalence between sites, ecological studies might be a
promising design to address patterns of occurrence of late neu-
ropsychiatric manifestations.
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